Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Eli Lilly has morphed from a reliable pharma giant into a biotech powerhouse riding blockbuster success. Mounjaro and ...

It won't come as a surprise to anyone to hear that quite a few quality stocks have performed terribly this year. Some have ...

Eli Lilly and Company (NYSE: LLY) today announced that data from studies of orforglipron, insulin efsitora alfa, tirzepatide ...

Novo Nordisk's early lead in weight-loss drugs fades as Eli Lilly surges ahead with more effective therapies and faster ...

The supply of GLP-1 drugs has been increasing, but they’re still expensive for most patients. Here are answers to some ...

Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels ...

In the wake of early evidence supporting the long-term health benefits of GLP-1 based medications to potentially reduce the ...

Discover how the breakthrough pill orforglipron matches injectable weight loss drugs in effectiveness while offering ...

The patent on weight loss injection semaglutide is due to expire in 2031, which will let other companies make cut-price ...

Viking Therapeutics has key trial catalysts ahead and trades near biotech deal valuations, despite dilution risks. Find out ...

Eli Lilly’s Alzheimer’s treatment, Kisunla (donanemab), scored a major win with approval in Australia, marking it as the ...